NCI-H2110 Cells
USD$550.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | NCI-H2110 is a human non-small cell lung cancer (NSCLC) cell line derived from a lung adenocarcinoma. Established as part of the NCI-Navy Medical Oncology Branch panel, this cell line is widely used for studying the biology of NSCLC and evaluating the efficacy of targeted and cytotoxic therapies. It grows as an adherent epithelial monolayer under standard in vitro conditions, typically cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum. Molecular profiling of NCI-H2110 has revealed an activating KRAS mutation, a key oncogenic driver that promotes constitutive activation of the MAPK/ERK and PI3K/AKT signaling pathways. This places the cell line among a subset of NSCLC models resistant to EGFR inhibitors but potentially sensitive to therapies targeting downstream effectors of KRAS signaling. Its mutation profile and pathway dependencies have made NCI-H2110 a valuable tool in pharmacogenomic analyses, including those exploring drug sensitivities across large cell line panels such as the Cancer Cell Line Encyclopedia (CCLE). In addition to its use in drug screening platforms, NCI-H2110 has been featured in transcriptomic and epigenomic studies that investigate chromatin accessibility, histone modifications, and gene expression patterns. Its well-characterized genetic background supports mechanistic studies of resistance to kinase inhibitors and helps elucidate the broader molecular landscape of KRAS-mutant lung adenocarcinomas. |
|---|---|
| Organism | Human |
| Tissue | Metastatic |
| Disease | Lung non-small cell carcinoma |
| Synonyms | H2110, H-2110, NCIH2110 |
Characteristics
| Age | Age unspecified |
|---|---|
| Gender | Sex unspecified |
| Ethnicity | African American |
| Cell type | Epithelial-like |
| Growth properties | Adherent |
Regulatory Data
| Citation | NCI-H2110 (Cytion catalog number 305838) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1530 |
Biomolecular Data
| Mutational profile | Mutation: RIT1, Simple, p.Met90Ile (c.270G>A), Heterozygous.Mutation, TP53, Simple, p.Arg158Pro (c.473G>C), Homozygous. |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305838-161025 | Certificate of Analysis | 05. Dec. 2025 | 305838 |
-
Related products
Related products